The Department of Health – Abu Dhabi (DoH), the emirate’s healthcare regulator, and mRNA Victoria, representing the State of Victoria in Australia, have signed a collaboration agreement to advance the global RNA ecosystem and further develop treatments related to COVID-19.
The agreement was signed by Dr. Jamal Mohammed Al Kaabi, Undersecretary of DoH, and by Mr. Michael Kapel, Chief Executive Officer, mRNA Victoria.
Both entities will identify areas of interest related to RNA research while initiating academic collaborations and knowledge exchange as well as identifying early-stage research investment opportunities. The collaboration will also explore clinical trial opportunities and private sector investment opportunities in both Abu Dhabi and the State of Victoria.
Abu Dhabi has solidified its status as a life science center and has been praised for its expertise in the COVID-19 pandemic response. The collaboration with the State of Victoria is only one of many aimed at improving the healthcare sector by enhancing capabilities and assuring preparedness.
With a focus on the development of a robust RNA ecosystem, both entities will be able to identify prospective partners and collaborate with organizations seeking to develop and license RNA-based therapeutics as well as manufacture innovative treatments. In addition, the agreement calls for the establishment of a steering committee consisting of members from the DoH and Victoria’s mRNA department to ensure alignment, effective execution, and implementation.
“Under the guidance of our wise leadership, Abu Dhabi registered a successful track record in its response to the COVID-19 pandemic. DoH continues to work towards adopting innovative treatment and breakthrough solutions in the UAE to ensure the safety and wellbeing of our community. With the signing of this collaboration agreement with the State of Victoria, we look forward to seeing the fruit of our collaboration when it comes to advancements in mRNA-based therapeutics research and strengthening the capabilities of the international healthcare system so that we are better prepared for future pandemics and health crises.”
Ms. Jaala Pulford, Minister for Innovation, Medical Research and the Digital Economy, Government of Victoria, said that “Victoria continues to lead the way in mRNA biotechnology and this agreement signifies a global collaboration to share knowledge, information and expertise within the ecosystem supporting supply chains research and development for pre-and clinical research, commercialization and manufacturing investments.”